Evidence map›Paper›PMID 37094891›Full record

ArticleBMJ open2023

Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study.

Christian Boisvert-Huneault, David Trigos Herraez, Andreas Pinter, Satomi Kobayashi, Stacie Bell, Kimberley Kallsen, Tristan Gloede, Nobutaka Yagi, Steven Brunette, Yakov Datsenko and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 5 countries.

Christian Boisvert-HuneaultCanadian Association of Psoriasis Patients, Ottawa, Ontario, Canada christianbh@hotmail.com.ORCID 0000-0002-2111-2517
David Trigos HerraezEUROPSO, European Umbrella Federation for Psoriasis Associations, Polzela, Slovenia.
Andreas PinterDepartment of Dermatology, Venereology and Allergology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany.
Satomi KobayashiDepartment of Dermatology, Seibo International Catholic Hospital, Tokyo, Japan.
Stacie BellNational Psoriasis Foundation, Portland, Oregon, USA.
Kimberley KallsenBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Tristan GloedeBoehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA.
Nobutaka YagiNippon Boehringer Ingelheim Co. Ltd, Tokyo, Japan.
Steven BrunetteBoehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA.
Yakov DatsenkoBoehringer Ingelheim International GmbH, Biberach, Germany.
Frank BaehnerBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Emmanuelle Clerisme-BeatyBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Peter Van de KerkhofDepartment of Dermatology, Radboud University, Nijmegen, The Netherlands.
Boehringer Ingelheim (Germany) · DEBoehringer Ingelheim (United States) · USBoehringer Ingelheim (Japan) · JPGoethe University Frankfurt · DENational Psoriasis Foundation · USPsoriasis Association · GBRadboud University Nijmegen · NLYokohama City Seibu Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesEvaluate the experiences and perceptions of patients participating in a simulated clinical trial and identify ways to enhance future patient-centric trial designs.

designInternational, multicentre, non-interventional, virtual clinical trial visits with patient debriefs and advisory boards.

settingVirtual clinic visits and accompanying advisory boards.

participantsNine patients with palmoplantar pustulosis for simulated trial visits; 14 patients and patient representatives for advisory boards.

main outcome measuresQualitative responses to trial documentation, visit schedule and logistics, and trial design were collected during patient debriefs. Results were discussed at two virtual advisory board meetings.

resultsPatients identified key barriers to participation and potential difficulties encountered when attending trial visits and completing assessments. They also proposed recommendations to overcome these challenges. Patients recognised the need for comprehensive informed consent forms, but recommended use of non-technical language, brevity and additional support to aid understanding. Other trial documentations should be relevant to the disease and include known efficacy and safety of the study drug. Patients were concerned about receiving placebo, stopping existing medications and being unable to receive the study drug after trial completion; therefore, patients and physicians recommended an open-label extension following trial completion. Trial visits were too numerous (n=20) and too long (3-4 hours each); patients recommended improvements to the design to make best use of their time and reduce unnecessary waiting. They also requested financial and logistical support. Patients expressed a desire for study outcomes that matter to them, related to their ability to undertake normal daily activities and not be a burden to others.

conclusionsSimulated trials are an innovative method for assessing trial design and acceptance from a patient-centric perspective, enabling specific improvements to be made prior to trial initiation. Incorporation of recommendations from simulated trials could enhance trial recruitment and retention, and optimise trial outcomes and data quality.

Indexed as

DERMATOLOGYPsoriasisSTATISTICS & RESEARCH METHODS

Identifiers

PMID37094891
PMCPMC10151841
OpenAlexW4366817589

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.